Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression EJ Aguilar, B Ricciuti, JF Gainor, KL Kehl, S Kravets, S Dahlberg, ... Annals of Oncology 30 (10), 1653-1659, 2019 | 269 | 2019 |
Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression≥ 50% JF Gainor, H Rizvi, EJ Aguilar, F Skoulidis, BY Yeap, J Naidoo, ... Annals of Oncology 31 (3), 404-411, 2020 | 97 | 2020 |
Metabolic reprogramming and dependencies associated with epithelial cancer stem cells independent of the epithelial-mesenchymal transition program E Aguilar, I Marin de Mas, E Zodda, S Marin, F Morrish, V Selivanov, ... Stem cells 34 (5), 1163-1176, 2016 | 93 | 2016 |
A key role for transketolase-like 1 in tumor metabolic reprogramming S Diaz-Moralli, E Aguilar, S Marin, JF Coy, M Dewerchin, MR Antoniewicz, ... Oncotarget 7 (32), 51875, 2016 | 58 | 2016 |
LKB1 deficiency in T cells promotes the development of gastrointestinal polyposis MC Poffenberger, A Metcalfe-Roach, E Aguilar, J Chen, BE Hsu, ... Science 361 (6400), 406-411, 2018 | 54 | 2018 |
Model-driven discovery of long-chain fatty acid metabolic reprogramming in heterogeneous prostate cancer cells I Marin de Mas, E Aguilar, E Zodda, C Balcells, S Marin, G Dallmann, ... PLOS Computational Biology 14 (1), e1005914, 2018 | 43 | 2018 |
Cancer cell metabolism as new targets for novel designed therapies IM de Mas, E Aguilar, A Jayaraman, IH Polat, A Martín-Bernabé, R Bharat, ... Future medicinal chemistry 6 (16), 1791-1810, 2014 | 33 | 2014 |
Mitochondrial protein UCP2 controls pancreas development B Broche, S Ben Fradj, E Aguilar, T Sancerni, M Bénard, F Makaci, ... Diabetes 67 (1), 78-84, 2018 | 31 | 2018 |
Cyclin-dependent kinases 4 and 6 control tumor progression and direct glucose oxidation in the pentose cycle M Zanuy, A Ramos-Montoya, O Villacanas, N Canela, A Miranda, ... Metabolomics 8, 454-464, 2012 | 30 | 2012 |
STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 2018; 8 (7): 822–835. doi: 10.1158/2159-8290 F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ... CD-18-0099, 0 | 27 | |
STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov 8: 822–835 F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ... | 16 | 2018 |
MIDcor, an R-program for deciphering mass interferences in mass spectra of metabolites enriched in stable isotopes VA Selivanov, A Benito, A Miranda, E Aguilar, IH Polat, JJ Centelles, ... BMC bioinformatics 18, 1-9, 2017 | 15 | 2017 |